Shots:

• ViGeneron to receive an up front and R&D funding for the mutually agreed workplan and will receive development- regulatory and commercial milestone payments along with royalties on sales of products arising from the collaborations
• ViGeneron will optimize and validate in vitro therapeutic candidates for undisclosed target to treat inherited eye disease while Biogen has the right to add an additional reserved target within two years after the effective date
• The companies will work together on the in vivo POC and will use ViGeneron’s vgAAV technology to efficiently transduce target cells via intravitreal injections

 ­ Ref: GlobeNewswire | Image:Biogen